China Nuokang Bio-Pharma (NKBP) Posts Mixed Q1 Results; Affirms Outlook
Tweet
Share
E-mailGet Alerts NKBP Hot Sheet
Join SI Premium – FREE
China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP) reported Q1 EPS of $0.08, $0.03 better than the analyst estimate of $0.05. Revenue for the quarter came in at $9.9 million versus the consensus estimate of $10.86 million.
Affirms outlook.
Affirms outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- KinderCare Learning Companies, Inc. (KLC) Misses Q2 EPS by 2c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
